SB

BPI 2026 · Biotech

Siren Biotechnology at BPI 2026

San Francisco, California

Siren Biotechnology brings 2 presentations to BPI 2026 in Boston. Its sessions follow the development of SRN-101 for high grade gliomas. One shows AAV gene therapy stability during convection-enhanced delivery, tracing the product from vial to brain.

OrganizationBPI 2026 Attendance
SB
Siren Biotechnology
San Francisco, California
1 SVP, Vector Development · 1 Director of Translational Research
Biotech
Develops AAV-based immuno-gene therapies for cancer, including high grade gliomas.
Talk
Fri Sep 25
10:00am–10:30am
From Vial to Brain: Demonstrating AAV Gene Therapy Stability During Convection-Enhanced Delivery
Gene Therapy Manufacturing & Analytics
Talk
Fri Sep 25
11:55am–12:15pm
The Siren Experience: Advancing SRN-101 for High Grade Gliomas
Development of Emerging Cell & Gene Therapies

Explore the full BPI 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full BPI 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Siren Biotechnology

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by Informa Connect or the BioProcess International Conference & Exhibition. Submit a correction